Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma.
Authors
Carlos Rojas
Centro de Investigacion Clinica, Bradford Hill, Santiago, Chile
Carlos Rojas , Baek-Yeol Ryoo , Sun Young Rha , Robin Kate Kelley , Ayala Hubert , Claudio Painemal , Raymond Couric Wadlow , Jun Gong , Li Fan , Fan Jin , Girish S. Naik , Teresa Macarulla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04976634
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr TPS425)
DOI
10.1200/JCO.2024.42.3_suppl.TPS425
Abstract #
TPS425
Poster Bd #
N10
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.
First Author: Robin Kate Kelley
Poster
2022 ASCO Annual Meeting
Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.
First Author: Robin Kate Kelley
Poster
2022 ASCO Annual Meeting
First-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress.
First Author: Jong-Mu Sun
Poster
2023 ASCO Annual Meeting
PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.
First Author: Manuel Rodrigues